Capsida Biotherapeutics, founded in Thousand Oaks, United States, is a pioneering biotechnology company dedicated to addressing monogenetic and sporadic central nervous system (CNS) and non-CNS disorders. Their core mission is to unlock the potential of gene therapy for all, aiming to transform the treatment landscape for these conditions. Capsida offers a fully integrated approach encompassing capsid engineering, discovery and preclinical research, manufacturing operations, and clinical development. Their market focus includes developing therapies for conditions such as Parkinson’s disease and genetic epilepsy.

Notable figures affiliated with Capsida include Peter Anastasiou, who plays a crucial role in steering the company towards its mission. The company has garnered significant attention and investment from leading biotech investors, contributing to its rapid advancements. Key achievements include the successful execution of IND-enabling studies, positioning them to initiate clinical trials. Capsida's innovative approach and comprehensive capabilities have made a significant impact on the gene therapy field, offering hope to patients with previously untreatable genetic disorders.